Balancing the benefits and risks of disease-modifying therapy in patients with multiple sclerosis

Journal of the Neurological Sciences

Volumn 311, Issue SUPPL. 1, 2011, Pages

  Sørensen, Per Soelberg ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Disease modifying treatments; Individualised treatment; Multiple sclerosis; Oral therapy; Riskbenefit management; Surrogate markers

Indexed keywords

BETA INTERFERON; BETA1A INTERFERON; CLADRIBINE; FINGOLIMOD; GLATIRAMER; METHYLPREDNISOLONE; MITOXANTRONE; NATALIZUMAB; PLACEBO; RITUXIMAB;

ADD ON THERAPY; ARTICLE; ATRIOVENTRICULAR BLOCK; BASAL CELL CARCINOMA; BONE MARROW TOXICITY; BRADYCARDIA; BREAST CANCER; CARDIOTOXICITY; DOCTOR PATIENT RELATION; DRUG EFFICACY; DRUG FATALITY; DRUG INDUCED CANCER; DRUG RESPONSE; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DYSPNEA; GASTROINTESTINAL SYMPTOM; HEART INFARCTION; HUMAN; INFECTION; LATENT TUBERCULOSIS; LEUKEMIA; MEDICAL DECISION MAKING; MELANOMA; MENOPAUSE; MULTIPLE SCLEROSIS; PANCREAS CANCER; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RETINA MACULA EDEMA; RISK BENEFIT ANALYSIS; SIDE EFFECT; SQUAMOUS CELL CARCINOMA; UNSPECIFIED SIDE EFFECT;

ADMINISTRATION, ORAL; ANTIBODIES, MONOCLONAL, HUMANIZED; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERFERON-BETA; MITOXANTRONE; MULTIPLE SCLEROSIS; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PEPTIDES; PHARMACOVIGILANCE; PROPYLENE GLYCOLS; RISK ASSESSMENT; SPHINGOSINE;

EID: 84855252396     PISSN: 0022510X     EISSN: 18785883     Source Type: Journal    
DOI: 10.1016/S0022-510X(11)70006-5     Document Type: Article

References (40)

1. CE Markowitz Interferon-beta: mechanism of action and dosing issues Neurology 68 2007 S8 11
2. O Neuhaus, C Farina, H Wekerle, R Hohlfeld Mechanisms of action of glatiramer acetate in multiple sclerosis Neurology 56 2001 702 708 (Pubitemid 32240087)
3. T Ziemssen, W Schrempf Glatiramer acetate: mechanisms of action in multiple sclerosis Int Rev Neurobiol 79 2007 537 570
4. LD Jacobs, DL Cookfair, RA Rudick, RM Herndon, JR Richert, AM Salazar et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG) Ann Neurol 39 1996 285 294 (Pubitemid 26100751)
5. KP Johnson, BR Brooks, JA Cohen, CC Ford, J Goldstein, RP Lisak et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group Neurology 45 1995 1268 1276
6. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis Lancet 352 1998 1498 1504
7. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group Neurology 43 1993 655 661
8. D Cadavid, LJ Wolansky, J Skurnick, J Lincoln, J Cheriyan, K Szczepanowski et al. Efficacy of treatment of MS with IFNb-1b or glatiramer acetate by monthly brain MRI in the BECOME study Neurology 72 2009 1976 1983
9. DD Mikol, F Barkhof, P Chang, PK Coyle, DR Jeffery, SR Schwid et al. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial Lancet Neurol 7 2008 903 914
10. P O'Connor, M Filippi, B Arnason, G Comi, S Cook, D Goodin et al. 250mug or 500mug interferon beta-1b versus 20mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study Lancet Neurol 8 2009 889 897
11. PS Sorensen, SI Mellgren, A Svenningsson, I Elovaara, JL Frederiksen, AG Beiske et al. NORdic trial of oral Methylprednisolone as add-on therapy to Interferon beta-1a for treatment of relapsing-remitting Multiple Sclerosis (NORMIMS study): a randomised, placebo-controlled trial Lancet Neurol 8 2009 519 529
12. CH Polman, PW O'Connor, E Havrdova, M Hutchinson, L Kappos, DH Miller et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis N Engl J Med 354 2006 899 910
13. HP Hartung, R Gonsette, N Konig, H Kwiecinski, A Guseo, SP Morrissey et al. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial Lancet 360 2002 2018 2025 (Pubitemid 36026580)
14. RA Rudick, WH Stuart, PA Calabresi, C Confavreux, SL Galetta, EW Radue et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis N Engl J Med 354 2006 911 923
15. BK Kleinschmidt-DeMasters, KL Tyler Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis N Engl J Med 353 2005 369 374 (Pubitemid 41132341)
16. A Langer-Gould, SW Atlas, AJ Green, AW Bollen, D Pelletier Progressive multifocal leukoencephalopathy in a patient treated with natalizumab N Engl J Med 353 2005 375 381 (Pubitemid 41132342)
17. HP Hartung New cases of progressive multifocal leukoencephalopathy after treatment with natalizumab Lancet Neurol 8 2009 28 31
18. L Kappos, D Bates, G Edan, M Eraksoy, A Garcia-Merino, N Grigoriadis et al. Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring Lancet Neurol 10 2011 745 758
19. P Iaffaldano, M D'Onghia, M Trojano Safety profile of Tysabri: international risk management plan Neurol Sci 30 Suppl 2 2009 S159 S162
20. RG Pratt, GA Boehm, CM Kortepeter, JA Racoosin Mitoxantrone treatment of multiple sclerosis: safety considerations Neurology 65 2005 1997 (Pubitemid 43970143)
21. V Martinelli, M Radaelli, L Straffi, M Rodegher, G Comi Mitoxantrone: benefits and risks in multiple sclerosis patients Neurol Sci 30 Suppl 2 2009 S167 S170
22. JJ Marriott, JM Miyasaki, G Gronseth, PW O'Connor Evidence Report: The efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology Neurology 74 2010 1463 1470
23. L Kappos, EW Radue, P O'Connor, C Polman, R Hohlfeld, P Calabresi et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis N Engl J Med 362 2010 387 401
24. JA Cohen, F Barkhof, G Comi, HP Hartung, BO Khatri, X Montalban et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis N Engl J Med 362 2010 402 415
25. G Giovannoni, G Comi, S Cook, K Rammohan, P Rieckmann, P Soelberg Sorensen et al. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis N Engl J Med 362 2010 416 426
26. J Rio, M Comabella, X Montalban Predicting responders to therapies for multiple sclerosis Nat Rev Neurol 5 2009 553 560
27. D Hesse, M Krakauer, H Lund, HB Sondergaard, A Langkilde, LP Ryder et al. Breakthrough disease during interferon-b therapy in MS: No signs of impaired biologic response Neurology 74 2010 1455 1462
28. C Lucchinetti, W Bruck, J Parisi, B Scheithauer, M Rodriguez, H Lassmann Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination Ann Neurol 47 2000 707 717 (Pubitemid 30390191)
29. H Lassmann, W Bruck, CF Lucchinetti The immunopathology of multiple sclerosis: an overview Brain Pathol 17 2007 210 218 (Pubitemid 46466140)
30. H Panitch, A Miller, D Paty, B Weinshenker Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study Neurology 63 2004 1788 1795 (Pubitemid 39532370)
31. European Study Group on interferon beta-1b in secondary progressive MS Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis Lancet 352 1998 1491 1497
32. JA Cohen, GR Cutter, JS Fischer, AD Goodman, FR Heidenreich, MF Kooijmans et al. Benefit of interferon beta-1a on MSFC progression in secondary progressive MS Neurology 59 2002 679 687
33. O Andersen, I Elovaara, M Farkkila, HJ Hansen, SI Mellgren, KM Myhr et al. Multicentre, randomised, double blind, placebo controlled, phase III study of weekly, low dose, subcutaneous interferon beta-1a in secondary progressive multiple sclerosis J Neurol Neurosurg Psychiatry 75 2004 706 710 (Pubitemid 38526680)
34. PS Sorensen, C Ross, KM Clemmesen, K Bendtzen, JL Frederiksen, K Jensen et al. Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis Lancet 362 2003 1184 1191 (Pubitemid 37255344)
35. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: experience during the first three years Neurology 47 1996 889 894
36. PRISMS Study Group and the University of British Columbia MS/MRI Analysis Group PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS Neurology 56 2001 1628 1636
37. L Kappos, M Clanet, M Sandberg-Wollheim, EW Radue, HP Hartung, R Hohlfeld et al. Neutralizing antibodies and efficacy of interferon beta-1a: a 4-year controlled study Neurology 65 2005 40 47 (Pubitemid 40967774)
38. V Tomassini, A Paolillo, P Russo, E Giugni, L Prosperini, C Gasperini et al. Predictors of long-term clinical response to interferon beta therapy in relapsing multiple sclerosis J Neurol 253 2006 287 293
39. J Rio, J Castillo, A Rovira, M Tintore, J Sastre-Garriga, A Horga et al. Measures in the first year of therapy predict the response to interferon beta in MS Mult Scler 15 2009 848 853
40. M Tintoré Rationale for early intervention with immunomodulatory treatments J Neurol 255 Suppl 1 2008 37 43 (Pubitemid 351341871)